T E Narasimhan, Hrishikesh Joshi &Amp;Amp; Sohini Das

Stories by T E Narasimhan, Hrishikesh Joshi &Amp;Amp; Sohini Das

Jeep To Drive Petrol Options For India

Jeep To Drive Petrol Options For India

Rediff.com   26 Sep 2023

The iconic brand is considering petrol powertrains for its entire Indian portfolio, which includes the Jeep Compass, Meridian, Grand Cherokee and Wrangler.

Govt in talks with SII for Nipah antibody, may put imports on hold

Govt in talks with SII for Nipah antibody, may put imports on hold

Rediff.com   21 Sep 2023

Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum Institute of India, report Shine Jacob and Sohini Das.

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Cipla, Torrent may need to divest 15 brands in buyout deal: Bernstein

Rediff.com   14 Sep 2023

As the market buzzes with news of Cipla promoters exiting the business through a stake sale and Ahmedabad-based Mehta family-led Torrent Pharmaceuticals racing to acquire its rival, Cipla, an analysis reveals that if the deal were to go through, both companies might need to divest as many as 15 brands to comply with Competition Commission of India (CCI) norms. A recent analysis by Bernstein shows that Cipla and Torrent share a presence in 332 products (based on product and molecule data from market research firm IQVIA). Bernstein analysts Nithya Balasubramanian and Parth Shah noted that, while this may appear as a high number, a significant portion of these products lack significance.

India's pharma industry likely to take 5-6% price hikes this year

India's pharma industry likely to take 5-6% price hikes this year

Rediff.com   6 Sep 2023

Notwithstanding the fact that the country's pharmaceutical (pharma) pricing regulator has allowed a 12 per cent price increase for medicines listed under the National List of Essential Medicines (NLEM) in 2023, analysts and industry insiders predict that the overall domestic pharma industry will only witness a price hike of 5-6 per cent. This is attributed to higher competitive intensity in the market. Krishnakumar V, executive director and chief operating officer (CEO) of Eris Lifesciences, a domestic-focused pharma company, noted that the NLEM segment experienced growth suppression of around 150 basis points due to price reductions during the January to July period this year.

From hatchbacks to holidays, consumers ready to loosen purse strings

From hatchbacks to holidays, consumers ready to loosen purse strings

Rediff.com   1 Sep 2023

With Onam and Raksha Bandhan just around the corner, the festival season is ready to kick off in full swing. As people embrace the celebratory spirit, companies anticipate a surge in sales this year. Consumer durables firms are expecting strong growth of 40-50 per cent in the premium segment during the upcoming season. Appliance makers also foresee increased demand for cooling appliances - refrigerators and air conditioners - which were impacted by unseasonal rainfall.

47,000 Luxury Cars To Be Sold This Year!

47,000 Luxury Cars To Be Sold This Year!

Rediff.com   28 Aug 2023

After a brief lull during the pandemic, there is a strong revival in luxury car sales, bolstered by more launches across price bands, replacement demand, ban on old diesel vehicles in the NCR, and 'revenge buying'.

Why All Is Not Well In Bharat Gears Family

Why All Is Not Well In Bharat Gears Family

Rediff.com   26 Aug 2023

The sons learned that they had been completely disinherited and that Surinder Kanwar's new wife would inherit everything.

'Power shifts to chemists instead of doctors'

'Power shifts to chemists instead of doctors'

Rediff.com   22 Aug 2023

'Whichever company offers better incentives, the chemist would prefer it.'

Why Dolo, Saridon, Calpol Will Have QR Codes

Why Dolo, Saridon, Calpol Will Have QR Codes

Rediff.com   8 Aug 2023

The top 300 pharmaceutical brands in the country will now bear a quick response (QR) code on their packaging to rein in spurious drugs and ensure better traceability.

Big pharma firms shift tack, look to bet on trade generics as volumes dip

Big pharma firms shift tack, look to bet on trade generics as volumes dip

Rediff.com   7 Aug 2023

Trade generic drugs (medicines that are sold directly through distributors) are fast becoming a key segment for domestic pharma firms as volume growth slows in the overall market. Big companies like Cipla and Alkem have a significant presence in the segment but recently, players like Torrent Pharmaceuticals and Dr Reddy's Laboratories (DRL) have also entered this market. What is driving big pharma's focus on trade generics? The volume growth in the Indian Pharma Market (IPM) has come down from 5.6 per cent in FY16 to 0.1 per cent in FY23.

M&M picks 3.5% stake in RBL Bank for Rs 417 cr, eyes to acquire more

M&M picks 3.5% stake in RBL Bank for Rs 417 cr, eyes to acquire more

Rediff.com   27 Jul 2023

Diversified business conglomerate Mahindra and Mahindra (M&M) has picked up a 3.53 per cent stake in private sector lender RBL Bank for Rs. 417 crore. "We may consider further investment, subject to pricing, regulatory approvals, and required procedures. However, in no circumstance will it exceed 9.9 per cent," M&M said in an exchange notification on Wednesday. Shares of RBL Bank jumped 7.1 per cent to settle at Rs. 238.8 apiece on the BSE on Wednesday, close to their 52-week high of Rs. 242.1.

Tata Motors applies for PLI benefits for Tiago electric car

Tata Motors applies for PLI benefits for Tiago electric car

Rediff.com   27 Jul 2023

Tata Motors, the market leader in electric four-wheeler space, has sought incentives for its Tiago EV under the government's production-linked incentive (PLI) scheme, group chief financial officer P B Balaji said on Tuesday. The Mumbai-headquartered firm has applied for all variants of the Tiago, which recently hit a sales milestone of 10,000 units. "The Automotive Research Association of India certification is done.

US drug shortage, stable pricing set to boost pharma revenues

US drug shortage, stable pricing set to boost pharma revenues

Rediff.com   24 Jul 2023

An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India's pharmaceutical companies during the first quarter of this financial year, analysts said. Most brokerages estimate a top line growth of around 14-15 per cent, with earnings before interest, taxes, depreciation, and amortisation (Ebitda) growth of 24-30 per cent for Q1 of FY24. Hospitals are, however, likely to report lower occupancy rates, and diagnostics companies may witness an impact from delayed monsoon.

Price hikes, lower input costs to aid auto firms' Q1

Price hikes, lower input costs to aid auto firms' Q1

Rediff.com   22 Jul 2023

Auto industry volumes have grown by 2.5 per cent overall, led by domestic sales of three-wheelers, two-wheelers and passenger vehicles (PVs) in the first quarter of this financial year. Analysts predict an 18 per cent growth in revenues for automotive original equipment manufacturers (OEMs) and profit growth of 69 per cent year-on-year (YoY). However, on a sequential basis, a decline in revenues as well as earnings before interest, taxes, depreciation, and amortisation (Ebitda) margins is expected.

What is Schedule M and why it's mandatory for all pharma units

What is Schedule M and why it's mandatory for all pharma units

Rediff.com   12 Jul 2023

With an eye on improving quality assurance in the wake of increased global scrutiny on Indian pharma products, the Centre on Tuesday said that Schedule M of the Drugs and Cosmetics Act, 1940 will be made compulsory for small and medium scale manufacturers in a phased manner. Union Health Minister Mansukh Mandaviya has asked micro-small and medium enterprises in pharma manufacturing to move towards good manufacturing practices (GMP) through self regulation. "This will help in quality assurance and also reduce compliance burden," Mandaviya.

As demand for EV batteries picks up, makers eye lithium reserves

As demand for EV batteries picks up, makers eye lithium reserves

Rediff.com   3 Jul 2023

The EV industry is at an inflection point and batteries will play a critical role ahead -- batteries and related components typically constitute 35-45 per cent of an EV's costs.

'Mercedes To Launch 10 Cars In 2023'

'Mercedes To Launch 10 Cars In 2023'

Rediff.com   3 Jul 2023

'And a majority will be in the top-end vehicle range.'

By 2025 Indian Trucks Will Have AC Cabin

By 2025 Indian Trucks Will Have AC Cabin

Rediff.com   3 Jul 2023

'Instead of ACs, the government should do something to increase our salary.'

2,300 Indian Students Return To Ukraine!

2,300 Indian Students Return To Ukraine!

Rediff.com   29 Jun 2023

About half of the students, who have been affected by the war, have taken admission to universities in other countries.

Regulatory woes torpedo PE/VC deals in e-pharma sector

Regulatory woes torpedo PE/VC deals in e-pharma sector

Rediff.com   27 Jun 2023

With regulatory uncertainties clouding the future of online pharmacies, deals in the space are showing signs of slowdown, as also fresh investment from private-equity (PE) firms and venture capitalists (VCs). The data from Venture Intelligence shows so far in 2023 (as of June 13) there has been one deal with PE-VC funding. In 2022 there were four, a sharp fall from the 12, totalling $1,520 million, the sector had attracted in 2021.